A rapid response of lung squamous cell carcinoma following treatment with sintilimab combined with recombinant humane endostatin injection and nab-paclitaxel in an elderly patient-Reference-Cited by-同舟云学术

A rapid response of lung squamous cell carcinoma following treatment with sintilimab combined with recombinant humane endostatin injection and nab-paclitaxel in an elderly patient

Published:2021-08-06 Issue:31 Volume:100 Page:e26801
ISSN:0025-7974
Container-title:Medicine
language:en
Short-container-title:

Author:

Fang Yueyu,Sun Hui,Chen Yi,Jiang Nanyuan,Ji Lianhua,Shi Junfeng

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference40 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J Clin,2018

2. Current and emergent therapy options for advanced squamous cell lung cancer;Socinski;J Thorac Oncol,2018

3. The integration of radiotherapy with immunotherapy for the treatment of non-small cell lung cancer;Ko;Clin Cancer Res,2018

4. PD-1 and its ligands in tolerance and immunity;Keir;Annu Rev Immunol,2008

5. Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1–11);Yang;J Thorac Oncol,2020

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of PD-1 inhibitors plus chemotherapy with or without endostatin for stage IV lung squamous cancer: a retrospective study;Frontiers in Immunology;2024-06-07

2. Chondroitin sulfate-based universal nanoparticle delivers angiogenic inhibitor and paclitaxel to exhibit a combination of chemotherapy and anti-angiogenic therapy;International Journal of Biological Macromolecules;2024-06